Ehab Hanna

University of Texas M. D. Anderson Cancer Center, Head and Neck Surgery, Faculty Member

Followers

Following

Co-authors

Public Views

Ehab Y. Hanna, M.D., FACS, is currently a Professor and Vice Chair of the Department of Head and Neck Surgery with a joint appointment in the Department of Neurosurgery, MD Anderson Cancer Center. He also serves as an Adjunct Professor of Otolaryngology and Head and Neck Surgery at Baylor College of Medicine. He is an internationally recognized head and neck surgeon and expert in the treatment of patients with skull base tumors and head and neck cancer. He is the medical director of the Multidisciplinary Head and Neck Center and co-director of the Skull Base Tumor program. For the last 15 years, Dr. Hanna has consistently been named one of America's Best Doctors and Top Doctors in Cancer. He authored over 350 publications. He co-edited several major textbooks such as Cancer of the Head and Neck and Comprehensive Management of Skull Base Tumors. He is the Editor-in-Chief of the journal of Head

less

Mark van den Boogaard

Radboud University Nijmegen

Nima M.NEJAT (moharamnejad)

Istanbul Aydin University

Heather Baid

University of Brighton

Arnaldo A da Silva

Hospital Israelita Albert Einstein

Gerben Breimer

University Medical Center Utrecht

Mohammad Alsultan

King Saud Bin Abdulaziz University for Health Sciences

Alireza Hedayatfar

Iran University of Medical Sciences

Hamed Mohammadi

Tabriz University Of Medical Sciences

George R Barclay

University of Edinburgh

Rossen Hazarbassanov

Universidade Federal de São Paulo (UNIFESP)

Interests

Uploads

Papers by Ehab Hanna

Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma

Head & neck, Jan 11, 2016

Background: Sinonasal undifferentiated carcinoma (SNUC) is a rare and aggressive cancer. Despite ... more Background: Sinonasal undifferentiated carcinoma (SNUC) is a rare and aggressive cancer. Despite multimodal therapy, the prognosis in SNUC remains poor, and new therapies are needed. Thus, we explored potential therapeutic targets in SNUC. Methods: Using the human-derived SNUC MDA8788-6 cell line, we performed whole genome single nucleotide polymorphism analysis to identify copy number changes in this line. Protein expression levels were evaluated by Western blotting. Cell growth inhibition was assessed by MTT and clonogenic assays. The mouse flank model was used to examine the effect of growth inhibition in vivo. Results: The ERBB2 gene was highly amplified and cell extracts showed HER2 was overexpressed and phosphorylated in MDA8788-6. Lapatinib effectively inhibited HER2 signaling pathway in our SNUC cell line. HER2 inhibition successfully suppressed the cell growth of MDA8788-6 cells both in vitro and in vivo. Conclusions: Targeting HER2 may be promising avenue for the development of novel therapies for SNUC.

Download

Feasibility of a Robotic Surgical Approach to Reconstruct the Skull Base

Skull Base Surgery, Jun 25, 2010

The role of robotic surgery in the skull base is evolving and represents the natural progression ... more The role of robotic surgery in the skull base is evolving and represents the natural progression toward maximizing surgical resections in confined spaces without compromising oncological principles. In this study, we describe the novel application of robotic surgery to the repair of dural defects in the skull base. A transmaxillary-transantral approach to the nasal cavity was performed bilaterally in a cadaveric model. Repair of the skull base defect was undertaken robotically. In this technical report, we demonstrate the feasibility of a suture-based technique for surgical reconstruction of the skull base with robotic assistance in a cadaveric model. In all cases, suture repair of dural defects was successfully performed with robotic-assisted technique. Although preliminary in nature, this study suggests that traditional suture techniques can be implemented in a confined surgical site with the use of robotic technology.

Download

Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial

Supportive Care in Cancer, Apr 29, 2019

Purpose-Local/systemic symptoms during cancer therapy may be exacerbated by dysregulated inflamma... more Purpose-Local/systemic symptoms during cancer therapy may be exacerbated by dysregulated inflammation and its downstream toxic effects. Minocycline can suppress proinflammatory cytokine release; therefore, we investigated its potential to reduce patient-reported symptom severity during radiotherapy (RT) for head and neck cancer (HNC). Methods-Eligible patients for this blinded, placebo-controlled trial were adults with T0-3, Nany, and M0 HNC receiving single-modality RT. Participants were randomized 1:1 to either minocycline (200 mg/day) or placebo during RT. The primary endpoint was the area under the curve (AUC) of 5 prespecified symptoms (pain, fatigue, disturbed sleep, poor appetite, difficulty swallowing/chewing) during RT, assessed with the MD Anderson Symptom Inventory for HNC (MDASI-HN). Results-We analyzed data from 20 evaluable patients per arm. Overall, 75% had oropharyngeal cancer and 78% were male. No grade 3+ adverse events potentially related to study medication were observed. Two minocycline patients required a feeding tube during RT vs 5 placebo patients (P = 0.21). The average daily AUC during RT for the 5 MDASI-HN symptoms was 3.1 (SD =1.0

Download

Soft Tissue Sarcomas of the Head and Neck Region with Skull Base/Intracranial Invasion: Review of Surgical Outcomes and Multimodal Treatment Strategies: A Retrospective Case Series

Current Oncology, Sep 14, 2022

This article is an open access article distributed under the terms and conditions of the Creative... more

Download

Robotic-Assisted Endoscopic Resection and Repair of the Anterior Skull Base

Skull Base Surgery, 2007

Drivers of Patient-Reported Symptom Interference During Radiation or Chemoradiation as Detected by the MD Anderson Symptom Inventory – Head and Neck Module

International Journal of Radiation Oncology Biology Physics, Oct 1, 2013

RTOG 0537 Phase 2/3 Study Comparing Acupuncture-Like Transcutaneous Electrical Nerve Stimulation ... more RTOG 0537 Phase 2/3 Study Comparing Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine (PC) in Treating Early Radiation-Induced Xerostomia (RIX): Phase 3 Preliminary Analysis R.K. Wong, S. Deshmukh, G. Wyatt, S.M. Sagar, A.K. Singh, K. Sultanem, P.F. Nguyen-Tan, S.S. Yom, S. Pugh, and L. Berk; McMaster University, Department of Oncology, Hamilton, ON, Canada, Radiation Therapy Oncology Group, Philadelphia, PA, Michigan State University, East Lansing, MI, Roswell Park Cancer Institute, Buffalo, NY, McGill University, Montreal, QC, Canada, Centre Hospitalier de l‘Universite de Montreal-Notre Dame, Montreal, QC, Canada, University of California San Francisco, San Francisco, CA, University of South Florida, Tampa, FL

Impact of Symptom Burden on Survival in Patients with Head and Neck Cancer Treated with Definitive Radiation Therapy

International Journal of Radiation Oncology Biology Physics, Nov 1, 2010

Minor salivary gland malignancies in the pediatric population

Head & neck, Jan 20, 2012

Minor salivary gland malignancies in children are rare and data on treatment and outcomes are lim... more Minor salivary gland malignancies in children are rare and data on treatment and outcomes are limited. A retrospective chart review of all pediatric patients with the pathologic diagnosis of minor salivary gland malignancy at a tertiary care cancer hospital was used to conduct this review. From 1952 to 2006, 35 children with minor salivary gland cancers were treated at The University of Texas MD Anderson Cancer Center. Mean age was 15.2 +/- 2.9 years with a slight female predominance. Recurrence occurred in 4 patients and was significantly associated with positive margins, advanced stage, and high histologic grade. Overall survival (OS) and disease-specific survival (DSS) were 89.3% and 88.4%, respectively, at 5 years. Advanced stage, positive margins, and high grade were associated with adverse survival. Minor salivary gland malignancies in children are rare. Surgical resection with clear margins yields excellent outcomes in patients with low-intermediate grade and early stage tumors. Patients with high-grade malignancies do poorly despite multimodality therapy.

Minocycline for reduction of patient-reported symptoms during radiation therapy for head and neck cancer: First results of a randomized trial

Journal of Clinical Oncology, May 20, 2014

6040 Background: Local and systemic symptoms during radiation therapy (RT) may be exacerbated by ... more 6040 Background: Local and systemic symptoms during radiation therapy (RT) may be exacerbated by dysregulated inflammation and its downstream toxic effects. Minocycline (mino) can suppress pro-inflammatory cytokine release. We conducted this study to investigate its potential to reduce patient (pt) reported symptom severity during RT for HNC. Methods: Eligible pts for this blinded, placebo-controlled trial were adults with oro- or nasopharyngeal carcinoma (T0-3, N-any, M0) dispositioned to intensity-modulated RT alone (no concurrent systemic therapy or prior resection). Participants were equally randomized to receive mino (100 mg twice daily) or placebo (P) during RT course. The primary endpoint was the area under the curve (AUC) of 5 pre-specified symptoms (pain, fatigue, sleep, appetite and swallowing) during RT course as assessed by the MDASI-HN (0-10 scale). As the overall goal of this study was to determine the potential signal/benefit of mino to inform future clinical trial design, we selected a mod...

Adenoid Cystic Carcinoma of the Skull Base: Results with an Aggressive Multidisciplinary Approach

Journal of neurological surgery, Feb 18, 2015

OBJECT Adenoid cystic carcinoma (ACC) is a locally aggressive tumor of salivary gland origin. Lit... more OBJECT Adenoid cystic carcinoma (ACC) is a locally aggressive tumor of salivary gland origin. Little data exist to guide treatment when this tumor extends to involve the structures of the skull base. METHODS Fifty-one patients with a diagnosis of ACC affecting the skull base were identified from a prospective database at MD Anderson Cancer Center (from 1992 to 2010). RESULTS Median follow-up for study patients was 6.75 years. The 5- and 10-year overall survival (OS) rates were 78% and 50%, respectively. Sixty-six percent of patients had progression of their disease. The 5- and 10-year progression-free survival (PFS) rates were 46.7% and 21.0%, respectively. Gross-total resection was achieved in 75% of patients, with 49% having microscopically negative margins at the time of first operation. On univariate analysis, resections with microscopically negative margins were associated with a significant OS advantage (20.1 ± 3.3 years) compared with resections that left residual disease, even if microscopic (10.3 ± 1.6 years, p = 0.035). In patients who underwent reoperation, the effect persisted, with improved OS in those with negative margins (21.4 ± 0.0 vs 16.7 ± 4.0 years, p = 0.06). The use of adjuvant radiotherapy was associated with an OS advantage (16.2 ± 2.5 vs 5.5 ± 2.2 years, p = 0.03) at initial diagnosis and improved PFS (7.8 ± 1.0 vs 2.1 ± 0.62 years, p = 0.005), whereas repeat irradiation provided no benefit. The use of adjuvant chemotherapy at diagnosis or at recurrence was not associated with any significant advantage. Multivariate analysis revealed margin-negative resection at initial operation and at recurrence retained OS significance, even after controlling for age, radiation therapy, and T stage. CONCLUSIONS ACC of the skull base is best treated with a multidisciplinary approach aimed at maximal, safe resection. Adjuvant radiotherapy should be offered, whereas chemotherapy does not confer benefit.

Adenoid Cystic Carcinoma of the Nasopharynx

Journal of neurological surgery, Mar 16, 2013

Supplementary Figure 4 from Establishment and Characterization of Novel Cell Lines from Sinonasal Undifferentiated Carcinoma

Download

Supplementary Figure 5 from Establishment and Characterization of Novel Cell Lines from Sinonasal Undifferentiated Carcinoma

PDF file - 169K, Tumorigenicity of MDA8788-7 cells. Tumorigenicity was examined by injecting cell... more PDF file - 169K, Tumorigenicity of MDA8788-7 cells. Tumorigenicity was examined by injecting cells into the flanks of the mice. (A) The cells injected into the flank without Matrigel formed in 75% of mice (6 of 8 mice). (B) By adding Matrigel, tumors grew much larger than the ones without adding Matrigel. (C) Average size of the tumors. (D) H& E staining from the tumor of the flank injection showed very similar appearance to the surgical specimen from the SNUC patient. The original magnifications x40 (left) and x200 (right).

Download

Outcomes for recurrent oral cavity squamous cell carcinoma

Oral Oncology

Induction Chemotherapy for Sinonasal Squamous Cell Carcinoma

Journal of Neurological Surgery Part B: Skull Base, 2018

Patient-, Disease-, and Treatment-Related Factors Affecting Progression-Free and Disease-Specific Survival in Recurrent Chondrosarcomas of the Skull Base

31st Annual Meeting North American Skull Base Society, 2022

Long‐Term Outcomes of Olfactory Neuroblastoma: MD Anderson Cancer Center Experience and Review of the Literature

The Laryngoscope, 2021

Objectives/HypothesisOlfactory neuroblastoma (ONB) is a rare sinonasal malignant neoplasm that is... more Objectives/HypothesisOlfactory neuroblastoma (ONB) is a rare sinonasal malignant neoplasm that is known to develop late recurrence. The aim of this study is to evaluate the long‐term outcomes of patients with ONB and to determine the factors associated with prognosis.Study DesignRetrospective study.MethodsA retrospective review of the medical records of 139 patients diagnosed with ONB at MD Anderson Cancer Center was performed between 1991 and 2016. Descriptive statistics were calculated, and Kaplan–Meier curves were utilized to assess survival.ResultsMedian follow‐up time was 75 months. Overall, 129 patients (92.8%) had surgery as part of their treatment and 82 (58.9%) patients received postoperative radiation therapy (PORT) or concurrent chemoradiotherapy. Endoscopic approaches were utilized for 72 patients, 69.4% of whom had pure endoscopic endonasal approaches. Five‐year overall survival and disease‐specific survival were 85.6% and 93.4%, respectively. Recurrence rate was 39.6% ...

Neoadjuvant chemotherapy for locoregionally advanced squamous cell carcinoma of the paranasal sinuses

Cancer, 2021

BackgroundSquamous cell carcinoma is the most common type of sinonasal malignancy. Despite improv... more BackgroundSquamous cell carcinoma is the most common type of sinonasal malignancy. Despite improvements in surgical resection and adjuvant therapy, which are considered the standard of care, the outcome for patients with locoregionally advanced disease remains poor. The objective of this study was to investigate the role of induction chemotherapy in patients with locoregionally advanced sinonasal squamous cell carcinoma and to determine the oncologic outcomes in those patients.MethodsThe study included 123 consecutive patients with previously untreated, locoregionally advanced (stage III and IV) sinonasal squamous cell carcinoma who were treated with curative intent at The University of Texas MD Anderson Cancer Center between 1988 and 2017 with induction chemotherapy followed by definitive local therapy. Patient demographics, tumor staging, treatment details, and oncologic outcomes were reviewed. The outcomes of this study included response to induction chemotherapy, recurrence, org...

Additional file 2: Table S2. of Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients â Ľ65Â years old

Results of univariate and multivariate analysis comparing MDASI-HN symptom item composite and Top... more

Long-Term Outcomes of Management of Olfactory Neuroblastoma: MD Anderson Experience

Journal of Neurological Surgery Part B: Skull Base, 2018

Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma

Head & neck, Jan 11, 2016

Download

Feasibility of a Robotic Surgical Approach to Reconstruct the Skull Base

Skull Base Surgery, Jun 25, 2010

Download

Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial

Supportive Care in Cancer, Apr 29, 2019